Overview
SCIENTIFIC SCORE
Moderately Effective
Based on 10 Researches
8.5
USERS' SCORE
Good
Based on 3 Reviews
8.5
Supplement Facts
Serving Size: 1 Tablet
Amount Per Serving
%DV
Folate (800 mcg L-methylfolate) (as L-methylfolate as Metafolin®)
1,333 mcg DFE
333%
Top Medical Research Studies
9
We explored innovative ways to improve cancer treatment by using folate-targeted nanoparticles. The study focused on the development of chitosan nanoparticles that mimic cell membranes, enhancing their ability to evade the immune system and prolong circulation in the body. By integrating folate, a nutrient known to target cancer cells, we hoped to increase the effectiveness of drug delivery directly to tumors.
Our findings revealed that these folate-targeted nanoparticles showed a remarkable capacity to be absorbed by breast cancer cells, specifically increasing uptake efficiency by five to six times compared to nanoparticles without folate. This was a significant boost, showcasing the potential of using folate as a guiding factor for cancer treatment.
Furthermore, the study demonstrated that these nanoparticles remained in the bloodstream for much longer, with their half-life extended from roughly 2.7 hours to nearly 13 hours. This means they can circulate longer and potentially reach tumors more effectively.
Ultimately, our research aims to pave the way for more efficient cancer therapies, highlighting how leveraging folate in nanoparticle design may provide a promising strategy in the fight against cancer.
Our findings revealed that these folate-targeted nanoparticles showed a remarkable capacity to be absorbed by breast cancer cells, specifically increasing uptake efficiency by five to six times compared to nanoparticles without folate. This was a significant boost, showcasing the potential of using folate as a guiding factor for cancer treatment.
Furthermore, the study demonstrated that these nanoparticles remained in the bloodstream for much longer, with their half-life extended from roughly 2.7 hours to nearly 13 hours. This means they can circulate longer and potentially reach tumors more effectively.
Ultimately, our research aims to pave the way for more efficient cancer therapies, highlighting how leveraging folate in nanoparticle design may provide a promising strategy in the fight against cancer.
Read More
8
We explored the potential of folate-decorated molecular spherical nucleic acids (MSNAs) as targeted delivery agents for cancer treatment. The study involved administering these specially formulated MSNAs to mice with breast cancer tumors and observing their biodistribution.
By using advanced imaging techniques, we found that the folate-decorated MSNAs accumulated more in tumors and other organs that express folate receptors (FRs), like the liver and kidneys. This higher concentration was particularly noted for MSNAs with specific backbone structures.
What stands out is how effective folate decoration enhances the targeting of cancer cells. The results suggest a promising avenue for improving the delivery of therapies specifically to FR-overexpressing cancers, while providing a clearer understanding of how folate can play a key role in cancer targeting strategies.
By using advanced imaging techniques, we found that the folate-decorated MSNAs accumulated more in tumors and other organs that express folate receptors (FRs), like the liver and kidneys. This higher concentration was particularly noted for MSNAs with specific backbone structures.
What stands out is how effective folate decoration enhances the targeting of cancer cells. The results suggest a promising avenue for improving the delivery of therapies specifically to FR-overexpressing cancers, while providing a clearer understanding of how folate can play a key role in cancer targeting strategies.
Read More
8
We set out to understand the effects of folate supplementation on the risk of skin cancers, particularly melanoma. Through a robust Mendelian randomization approach, we examined genetic data linked to vitamin supplementation to analyze potential causal relationships.
Our findings indicate that folate supplementation appears to have a protective effect, significantly reducing the risk of melanoma. The results were supported by both observational data and genetic analysis, ensuring a comprehensive understanding of the association.
While our focus was primarily on folate, we acknowledge that further studies are necessary to evaluate the effects of other vitamins on skin cancer risk. Overall, this research provides valuable insights into how certain dietary supplements, like folate, might play a role in preventing skin cancers.
Our findings indicate that folate supplementation appears to have a protective effect, significantly reducing the risk of melanoma. The results were supported by both observational data and genetic analysis, ensuring a comprehensive understanding of the association.
While our focus was primarily on folate, we acknowledge that further studies are necessary to evaluate the effects of other vitamins on skin cancer risk. Overall, this research provides valuable insights into how certain dietary supplements, like folate, might play a role in preventing skin cancers.
Read More
Most Useful Reviews
9
Cancer protection
37 people found this helpful
Folic acid is essential, especially for those preparing for pregnancy or with a deficiency. It offers powerful protection against cancer. This bottle contains the ideal form of folic acid for our bodies!
Read More
6
Cancer risk reduction
This is a good product from a reputable manufacturer. Folic acid (vitamin B9) aids in the production of happiness hormones, supports hematopoiesis, boosts the immune system, and controls cell division. It also reduces the risk of breast, ovarian, and colon cancer. I've given it to my child with a neurological diagnosis alongside other medications. While improvements are noticeable, it is essential that B9 is taken with B12 for optimal effectiveness.
Read More
7.5
Positive effects
1 people found this helpful
I am highly pleased and will continue reordering regularly. Research has shown Metafolin Folate is crucial for cancer patients, and I have recommended it to a family member.
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 10 Researches
8.5
- All Researches
9
We explored how the folate receptor alpha (FRα) can be a promising target in treating resistant germ cell tumors (GCTs), which often have poor outcomes due to limited therapeutic options. Our research centered on mirvetuximab soravtansine (MIRV), an antibody-drug conjugate that specifically targets FRα, which is frequently overexpressed in many cancer types, including GCTs.
Through our experiments, we observed that FRα levels were significantly higher in several GCT cell lines as compared to normal tissue. When we treated cisplatin-resistant GCT cells with MIRV, we found it not only triggered cell death but also had a strong effect on unintended bystander cells in direct coculture experiments. This suggests that the treatment may extend its reach beyond just the targeted cancer cells.
Additionally, we confirmed through immunohistochemistry that FRα protein expression is notably elevated in GCT patients after chemotherapy, especially in those with unfavorable prognoses. Our findings emphasize the need for further exploration of FRα-targeting therapies as a potential treatment option for GCTs, particularly those that do not respond well to current therapies. MIRV shows significant antitumor effects and encourages further studies into its use in battling treatment-resistant GCTs.
Through our experiments, we observed that FRα levels were significantly higher in several GCT cell lines as compared to normal tissue. When we treated cisplatin-resistant GCT cells with MIRV, we found it not only triggered cell death but also had a strong effect on unintended bystander cells in direct coculture experiments. This suggests that the treatment may extend its reach beyond just the targeted cancer cells.
Additionally, we confirmed through immunohistochemistry that FRα protein expression is notably elevated in GCT patients after chemotherapy, especially in those with unfavorable prognoses. Our findings emphasize the need for further exploration of FRα-targeting therapies as a potential treatment option for GCTs, particularly those that do not respond well to current therapies. MIRV shows significant antitumor effects and encourages further studies into its use in battling treatment-resistant GCTs.
Read More
9
We set out to explore how folate can improve treatment strategies for breast cancer, particularly in the HER2-positive subtype. To do this, we designed lipid nanoparticles (LNPs) that could deliver DNA targeted specifically at breast cancer cells. The exciting part was that we used a combination of trastuzumab, a monoclonal antibody that targets HER2, and folate to enhance how effectively these nanoparticles reached the cancer cells.
In our experiments, we created LNPs that captured a DNA plasmid coding for a fluorescent protein. This allowed us to track the effectiveness of our dual-targeting strategy in different breast cancer cell lines. The results were compelling; we found that pairing trastuzumab with folate significantly increased cellular uptake and expression of the delivered DNA when compared to using trastuzumab alone. This indicates that folate plays a crucial role in enhancing the effectiveness of targeted treatments.
Additionally, we conducted tests using zebrafish to confirm that our dual-targeted nanoparticles demonstrated better targeting and transfection under realistic biological conditions. Overall, our findings suggest that this dual-targeting method may provide a more effective approach to delivering therapeutic DNA to HER2-positive breast cancer cells, showcasing the potential for incorporating folate in future cancer treatment strategies.
In our experiments, we created LNPs that captured a DNA plasmid coding for a fluorescent protein. This allowed us to track the effectiveness of our dual-targeting strategy in different breast cancer cell lines. The results were compelling; we found that pairing trastuzumab with folate significantly increased cellular uptake and expression of the delivered DNA when compared to using trastuzumab alone. This indicates that folate plays a crucial role in enhancing the effectiveness of targeted treatments.
Additionally, we conducted tests using zebrafish to confirm that our dual-targeted nanoparticles demonstrated better targeting and transfection under realistic biological conditions. Overall, our findings suggest that this dual-targeting method may provide a more effective approach to delivering therapeutic DNA to HER2-positive breast cancer cells, showcasing the potential for incorporating folate in future cancer treatment strategies.
Read More
9
We aimed to explore how folate’s targeting capabilities can enhance the treatment of glioblastoma multiforme, a dangerous type of brain cancer with very low survival rates. Our study focused on creating specialized nanoparticles that encapsulate ibrutinib, a drug that inhibits cancer cell growth, and examined whether these folate-based nanoparticles could more effectively deliver the medication to cancer cells.
Through our experiments, we discovered that the new folate-targeted nanoparticles significantly improved the uptake of the drug into glioma cells. This was evident as we observed uptake rates rise dramatically in different cell lines, indicating that the folate receptor may be an effective means of directing treatment where it's most needed.
Additionally, the treatment with these folate-targeted nanoparticles resulted in a meaningful reduction in tumor size compared to standard treatment methods. The results suggest that by enhancing the delivery of ibrutinib through a targeted approach, we can potentially improve outcomes for patients with this challenging condition.
Through our experiments, we discovered that the new folate-targeted nanoparticles significantly improved the uptake of the drug into glioma cells. This was evident as we observed uptake rates rise dramatically in different cell lines, indicating that the folate receptor may be an effective means of directing treatment where it's most needed.
Additionally, the treatment with these folate-targeted nanoparticles resulted in a meaningful reduction in tumor size compared to standard treatment methods. The results suggest that by enhancing the delivery of ibrutinib through a targeted approach, we can potentially improve outcomes for patients with this challenging condition.
Read More
9
FLOT regimen shows treatment promise
We aimed to explore the effectiveness of the FLOT chemotherapy regimen, which incorporates folate, in treating locally advanced gastric cancer. Our study focused on patients who received this treatment from 2017 to 2020, assessing their responses to chemotherapy based on a measure called tumor regression grade (TRG).
Our findings indicated that a significant portion of patients responded well to the therapy, with nearly 30% achieving either a complete or moderate response. Notably, we discovered that lymphovascular invasion—when cancer spreads to the lymphatic system—can help predict these responses.
Crucially, patients who showed positive histopathological responses had much better outcomes, boasting impressive two-year disease-free survival and overall survival rates. With only a small number suffering from severe side effects, the FLOT regimen demonstrates a favorable toxicity profile. Although folate is a component of this treatment, its isolated impact is difficult to deduce since it works in combination with several other medications.
Overall, our results highlight the potential of the FLOT regimen in providing effective treatment options for gastric cancer patients, emphasizing improved survival rates for those who respond positively to chemotherapy.
Our findings indicated that a significant portion of patients responded well to the therapy, with nearly 30% achieving either a complete or moderate response. Notably, we discovered that lymphovascular invasion—when cancer spreads to the lymphatic system—can help predict these responses.
Crucially, patients who showed positive histopathological responses had much better outcomes, boasting impressive two-year disease-free survival and overall survival rates. With only a small number suffering from severe side effects, the FLOT regimen demonstrates a favorable toxicity profile. Although folate is a component of this treatment, its isolated impact is difficult to deduce since it works in combination with several other medications.
Overall, our results highlight the potential of the FLOT regimen in providing effective treatment options for gastric cancer patients, emphasizing improved survival rates for those who respond positively to chemotherapy.
Read More
9
We observed a compelling case where a 70-year-old woman battling advanced sigmoid colon cancer underwent a transformative treatment. Initially, she presented with significant weight loss and a lack of appetite. A colonoscopy and CT scan revealed that her cancer had invaded the bladder and left ovary, with enlarged lymph nodes indicating an advanced stage.
Faced with a large tumor, the medical team opted for pre-operative chemotherapy before surgical intervention. Notably, the patient's RAS gene was free of mutations, making her a candidate for the mFOLFOX6 regimen alongside cetuximab—a strategic choice. Throughout the six courses of chemotherapy, despite experiencing Grade 3 neutropenia, she did not face intolerable side effects.
Remarkably, the treatment led to a significant reduction in tumor size, paving the way for an open resection of her sigmoid colon, bladder wall, and left ovarian cyst. Post-surgery, she recovered well and was discharged after just ten days. Histopathology revealed that the tumor was a moderately differentiated adenocarcinoma, classified as ypT4b, ypN0, M0, and ypStage IIc, all with clear surgical margins. Encouragingly, she remained free of recurrence for six months after surgery, highlighting the effectiveness of the cetuximab combination regimen in her treatment journey.
Faced with a large tumor, the medical team opted for pre-operative chemotherapy before surgical intervention. Notably, the patient's RAS gene was free of mutations, making her a candidate for the mFOLFOX6 regimen alongside cetuximab—a strategic choice. Throughout the six courses of chemotherapy, despite experiencing Grade 3 neutropenia, she did not face intolerable side effects.
Remarkably, the treatment led to a significant reduction in tumor size, paving the way for an open resection of her sigmoid colon, bladder wall, and left ovarian cyst. Post-surgery, she recovered well and was discharged after just ten days. Histopathology revealed that the tumor was a moderately differentiated adenocarcinoma, classified as ypT4b, ypN0, M0, and ypStage IIc, all with clear surgical margins. Encouragingly, she remained free of recurrence for six months after surgery, highlighting the effectiveness of the cetuximab combination regimen in her treatment journey.
Read More
User Reviews
USERS' SCORE
Good
Based on 3 Reviews
8.5
- All Reviews
- Positive Reviews
- Negative Reviews
9
Cancer protection
37 people found this helpful
Folic acid is essential, especially for those preparing for pregnancy or with a deficiency. It offers powerful protection against cancer. This bottle contains the ideal form of folic acid for our bodies!
Read More
6
Cancer risk reduction
This is a good product from a reputable manufacturer. Folic acid (vitamin B9) aids in the production of happiness hormones, supports hematopoiesis, boosts the immune system, and controls cell division. It also reduces the risk of breast, ovarian, and colon cancer. I've given it to my child with a neurological diagnosis alongside other medications. While improvements are noticeable, it is essential that B9 is taken with B12 for optimal effectiveness.
Read More
7.5
Positive effects
1 people found this helpful
I am highly pleased and will continue reordering regularly. Research has shown Metafolin Folate is crucial for cancer patients, and I have recommended it to a family member.
Read More
Frequently Asked Questions
6
Cancer risk reduction
This is a good product from a reputable manufacturer. Folic acid (vitamin B9) aids in the production of happiness hormones, supports hematopoiesis, boosts the immune system, and controls cell division. It also reduces the risk of breast, ovarian, and colon cancer. I've given it to my child with a neurological diagnosis alongside other medications. While improvements are noticeable, it is essential that B9 is taken with B12 for optimal effectiveness.
7.5
Positive effects
1 people found this helpful
I am highly pleased and will continue reordering regularly. Research has shown Metafolin Folate is crucial for cancer patients, and I have recommended it to a family member.
9
Cancer protection
37 people found this helpful
Folic acid is essential, especially for those preparing for pregnancy or with a deficiency. It offers powerful protection against cancer. This bottle contains the ideal form of folic acid for our bodies!
9
We explored how the folate receptor alpha (FRα) can be a promising target in treating resistant germ cell tumors (GCTs), which often have poor outcomes due to limited therapeutic options. Our research centered on mirvetuximab soravtansine (MIRV), an antibody-drug conjugate that specifically targets FRα, which is frequently overexpressed in many cancer types, including GCTs.
Through our experiments, we observed that FRα levels were significantly higher in several GCT cell lines as compared to normal tissue. When we treated cisplatin-resistant GCT cells with MIRV, we found it not only triggered cell death but also had a strong effect on unintended bystander cells in direct coculture experiments. This suggests that the treatment may extend its reach beyond just the targeted cancer cells.
Additionally, we confirmed through immunohistochemistry that FRα protein expression is notably elevated in GCT patients after chemotherapy, especially in those with unfavorable prognoses. Our findings emphasize the need for further exploration of FRα-targeting therapies as a potential treatment option for GCTs, particularly those that do not respond well to current therapies. MIRV shows significant antitumor effects and encourages further studies into its use in battling treatment-resistant GCTs.
Through our experiments, we observed that FRα levels were significantly higher in several GCT cell lines as compared to normal tissue. When we treated cisplatin-resistant GCT cells with MIRV, we found it not only triggered cell death but also had a strong effect on unintended bystander cells in direct coculture experiments. This suggests that the treatment may extend its reach beyond just the targeted cancer cells.
Additionally, we confirmed through immunohistochemistry that FRα protein expression is notably elevated in GCT patients after chemotherapy, especially in those with unfavorable prognoses. Our findings emphasize the need for further exploration of FRα-targeting therapies as a potential treatment option for GCTs, particularly those that do not respond well to current therapies. MIRV shows significant antitumor effects and encourages further studies into its use in battling treatment-resistant GCTs.
8
We explored a new approach to combat the difficulties cancer presents in treatment, specifically targeting immune evasion within tumors. The study focused on a unique delivery system that combines folate with an exosome inhibitor and an immune-activating gene. By utilizing folate, researchers aimed to deliver the treatment directly to cancer cells and tumor-associated macrophages effectively.
The results were promising. We observed that the folate-modified system successfully reduced tumor-derived exosomes, which can hinder the immune response, particularly those containing PD-L1 that suppress the immune system. Furthermore, the study indicated that silencing a specific gene (IRF3) not only limited the differentiation of macrophages that promote tumor growth but also helped reduce the recruitment of regulatory T cells that can dampen the immune response.
When paired with an existing immunotherapy (a-PD-1), this dual delivery method demonstrated enhanced antitumor effects, resulting in increased cytotoxic T cell activity and decreased polarization of harmful macrophages. This research suggests that folate can play a pivotal role in enhancing cancer treatment by improving immune responses against tumors, indicating a significant step toward more effective therapies.
The results were promising. We observed that the folate-modified system successfully reduced tumor-derived exosomes, which can hinder the immune response, particularly those containing PD-L1 that suppress the immune system. Furthermore, the study indicated that silencing a specific gene (IRF3) not only limited the differentiation of macrophages that promote tumor growth but also helped reduce the recruitment of regulatory T cells that can dampen the immune response.
When paired with an existing immunotherapy (a-PD-1), this dual delivery method demonstrated enhanced antitumor effects, resulting in increased cytotoxic T cell activity and decreased polarization of harmful macrophages. This research suggests that folate can play a pivotal role in enhancing cancer treatment by improving immune responses against tumors, indicating a significant step toward more effective therapies.
9
We set out to explore how folate can improve treatment strategies for breast cancer, particularly in the HER2-positive subtype. To do this, we designed lipid nanoparticles (LNPs) that could deliver DNA targeted specifically at breast cancer cells. The exciting part was that we used a combination of trastuzumab, a monoclonal antibody that targets HER2, and folate to enhance how effectively these nanoparticles reached the cancer cells.
In our experiments, we created LNPs that captured a DNA plasmid coding for a fluorescent protein. This allowed us to track the effectiveness of our dual-targeting strategy in different breast cancer cell lines. The results were compelling; we found that pairing trastuzumab with folate significantly increased cellular uptake and expression of the delivered DNA when compared to using trastuzumab alone. This indicates that folate plays a crucial role in enhancing the effectiveness of targeted treatments.
Additionally, we conducted tests using zebrafish to confirm that our dual-targeted nanoparticles demonstrated better targeting and transfection under realistic biological conditions. Overall, our findings suggest that this dual-targeting method may provide a more effective approach to delivering therapeutic DNA to HER2-positive breast cancer cells, showcasing the potential for incorporating folate in future cancer treatment strategies.
In our experiments, we created LNPs that captured a DNA plasmid coding for a fluorescent protein. This allowed us to track the effectiveness of our dual-targeting strategy in different breast cancer cell lines. The results were compelling; we found that pairing trastuzumab with folate significantly increased cellular uptake and expression of the delivered DNA when compared to using trastuzumab alone. This indicates that folate plays a crucial role in enhancing the effectiveness of targeted treatments.
Additionally, we conducted tests using zebrafish to confirm that our dual-targeted nanoparticles demonstrated better targeting and transfection under realistic biological conditions. Overall, our findings suggest that this dual-targeting method may provide a more effective approach to delivering therapeutic DNA to HER2-positive breast cancer cells, showcasing the potential for incorporating folate in future cancer treatment strategies.
8
We set out to understand the effects of folate supplementation on the risk of skin cancers, particularly melanoma. Through a robust Mendelian randomization approach, we examined genetic data linked to vitamin supplementation to analyze potential causal relationships.
Our findings indicate that folate supplementation appears to have a protective effect, significantly reducing the risk of melanoma. The results were supported by both observational data and genetic analysis, ensuring a comprehensive understanding of the association.
While our focus was primarily on folate, we acknowledge that further studies are necessary to evaluate the effects of other vitamins on skin cancer risk. Overall, this research provides valuable insights into how certain dietary supplements, like folate, might play a role in preventing skin cancers.
Our findings indicate that folate supplementation appears to have a protective effect, significantly reducing the risk of melanoma. The results were supported by both observational data and genetic analysis, ensuring a comprehensive understanding of the association.
While our focus was primarily on folate, we acknowledge that further studies are necessary to evaluate the effects of other vitamins on skin cancer risk. Overall, this research provides valuable insights into how certain dietary supplements, like folate, might play a role in preventing skin cancers.
7
We explored the relationship between folate and glutamine metabolism and their influence on kidney cancer prognosis. Our analysis included expression and survival studies, and we utilized various platforms to gather critical data on specific genes linked to these metabolic pathways.
By focusing on genes such as SLC1A5 and MTHFD2, we noted a pattern: higher expression levels of these genes were connected to more advanced tumor stages and greater instances of lymph node metastasis in kidney cancer patients. Interestingly, we found that elevated serum folate levels might be associated with improved cancer-specific survival outcomes, suggesting that folate could potentially play a role in better prognosis for those diagnosed with kidney cancer.
Our findings indicate that glutamine metabolism appears to work in tandem with folate metabolism, highlighting a complex relationship that warrants further investigation. Overall, the relationship between folate levels and kidney cancer suggests promising implications for patient outcomes, meriting deeper exploration in future studies.
By focusing on genes such as SLC1A5 and MTHFD2, we noted a pattern: higher expression levels of these genes were connected to more advanced tumor stages and greater instances of lymph node metastasis in kidney cancer patients. Interestingly, we found that elevated serum folate levels might be associated with improved cancer-specific survival outcomes, suggesting that folate could potentially play a role in better prognosis for those diagnosed with kidney cancer.
Our findings indicate that glutamine metabolism appears to work in tandem with folate metabolism, highlighting a complex relationship that warrants further investigation. Overall, the relationship between folate levels and kidney cancer suggests promising implications for patient outcomes, meriting deeper exploration in future studies.
References
- Kucerova L, Fekiacova A, Udvorkova N, Malcharkova P, Blahova V, et al. Mirvetuximab Soravtansine Induces Potent Cytotoxicity and Bystander Effect in Cisplatin-Resistant Germ Cell Tumor Cells. Cells. 2025;14. doi:10.3390/cells14040287
- Kim J, Kim M, Han H, Kim S, Lahiji SF, et al. Dual-delivery of exosome inhibitor and immune-activating gene via lipid nano-assemblies for tumor immune evasion inhibition. J Control Release. 2025;381:113569. doi:10.1016/j.jconrel.2025.02.065
- Auchynnikava T, Äärelä A, Moisio O, Liljenbäck H, Andriana P, et al. Biological Evaluation of Molecular Spherical Nucleic Acids: Targeting Tumors via a Hybridization-Based Folate Decoration. ACS Omega. 2025;10:6003. doi:10.1021/acsomega.4c10047
- Lotter C, Stierli MA, Puligilla RD, Huwyler J. Dual targeted lipid nanoparticles for enhanced DNA delivery and transfection of breast cancer cells. Eur J Pharm Biopharm. 2025. doi:10.1016/j.ejpb.2025.114674
- Qi P, Chen L, Ma A, Zhang Y, Lin H, et al. Genetically predicted vitamins supplementation and risk of skin cancers: a Mendelian randomization study. Discov Oncol. 2025;16:204. doi:10.1007/s12672-025-01905-9
- Morshedi B, Esfandyari-Manesh M, Atyabi F, Ghahremani MH, Dinarvand R. Local delivery of ibrutinib by folate receptor-mediated targeting PLGA-PEG nanoparticles to glioblastoma multiform: and studies. J Drug Target. 2025. doi:10.1080/1061186X.2025.2468749
- Atci MM, Secmeler S, Sakin A, Arici S, Can O, et al. Perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in gastric cancer: Pathological regression grade and its relationship to clinical outcome. Indian J Cancer. 2024;61:714. doi:10.4103/ijc.IJC_1283_20
- Qin J, Ouyang C, Zhuang X. Association between folate and glutamine metabolism and prognosis of kidney cancer. Front Nutr. 2024;11:1506967. doi:10.3389/fnut.2024.1506967
- Konishi K, Fukumoto Y, Minoji T, Muranishi K, Nishigaki T, et al. [A Case of Sigmoid Colon Cancer with Bladder Invasion Successfully Treated with Chemotherapy with mFOLFOX6+Cetuximab]. Gan To Kagaku Ryoho. 2024;51:1797.
- Xie M, Zhao J, Feng X, Gao X, Cheng W, et al. Cell membrane-inspired chitosan nanoparticles for prolonged circulation and tumor-targeted drug delivery. Int J Biol Macromol. 2025;304:140934. doi:10.1016/j.ijbiomac.2025.140934
